BNET Industries

Sepracor Inc.

(SEPR) is in the Pharma Industry

Last Fiscal Year Sales:$1.2B
  • Public
  • US
Dow Jones Description

Founded in 1984, Sepracor was originally comprised of several diverse business units. In 1989, we embarked on a strategy of developing single isomers and active metabolites of many of the world's largest selling drugs, with the objective of developing our own proprietary pipeline of pharmaceutical products. Sepracor became a publicly traded corporation in 1991, and we subsequently divested our non-pharmaceutical business units into four different companies, retaining our core pharmaceutical business. Sepracor was built on the premise that chiral drugs could, in essence, be divided into two or more "parts" and that certain of these parts could be brought to the market as new medicines with the possibility for reduced side effects, greater potency or new indications. Sepracor was a pioneer in this area of drug development, identifying new, viable compounds. This strategy enabled Sepracor to establish itself initially by out-licensing the rights to a number of compounds to large, established pharmaceutical companies who developed and ultimately commercialized them. Some of these compounds have grown to become well-known brands in the pharmaceutical industry: ALLEGRA brand fexofenadine HCl, CLARINEX brand desloratadine and XYZAL /XUSALTM brand levocetirizine. ...

Number of Employees 2,400
Contact Information

84 Waterford Dr

Marlborough, Massachusetts 01752

sepracor.com

(508) 481-6700

NAICS Code Pharmaceutical and Medicine Manufacturing: 3254

Recent Events

  • Sepracor CEO in line for $11M golden handshake

    10/22/09 - Merger / Acquisition - View Story

  • Data Missing On US Drug Labels

    10/23/09 - Financial Announcement - View Story

  • Sepracor deal closes, CEO in line for $11M

    10/21/09 - Merger / Acquisition - View Story

  • Standard & Poor's Announces Changes To U.S. Indices - Update

    10/07/09 - Merger / Acquisition - View Story

  • Levi & Korsinsky, LLP Announces Class Action Lawsuit Against Sepracor, Inc. -- SEPR

    9/11/09 - Lawsuit Filed - View Story

  • Sepracor investors try to derail $2.6B Dainippon buyout

    9/09/09 - Product Announcement - View Story

  • Japanese Pharma on the Move Again With Lots of Acquisitions, Globalization

    9/10/09 - Merger / Acquisition - View Story

  • Dainippon Sumitomo to buy Sepracor

    9/06/09 - Licensing / Contract - View Story

  • Dainippon Agrees to Buy Sepracor

    9/04/09 - Merger / Acquisition - View Story

  • Sepracor to Merge With Dainippon in $2.6 Billion Deal

    9/04/09 - Merger / Acquisition - View Story

  • Nikkei nudges down 0.2 pct, Daiwa and SMFG slip

    9/04/09 - Merger / Acquisition - View Story

  • Willkie Farr and Paul Weiss on $2.6 Billion Japanese Pharma Deal

    9/03/09 - Licensing / Contract - View Story

  • Asian markets mixed as China soars while US data weighs

    9/03/09 - Merger / Acquisition - View Story

  • Sepracor Accepts $2.6 Billion Dainippon Bid

    9/03/09 - Merger / Acquisition - View Story

  • Stocks Await Service Sector Data To Break Lackluster Phase - RTTNews Daily Market Analysis

    9/03/09 - Merger / Acquisition - View Story

  • Japanese company to buy Sepracor for $2.6 billion

    9/03/09 - Merger / Acquisition - View Story

  • Dainippon to buy Sepracor

    9/03/09 - Joint Venture / Alliance - View Story

  • Dainippon Sumitomo Pharma to acquire Sepracor for $2.6 billion

    9/05/09 - Merger / Acquisition - View Story

News & Analysis

fda and sepracor inc. - All News and Analysis